Momenta Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (23)

View All

Latest Posts

About This Stock More About This Stock
Healthcare & Biotechs Struggle, But Opportunity Ahead
Article By: Tarun Chandra, CFA
Wednesday, October 23, 2019 2:24 AM EDT
Improving risk appetite is nudging markets higher, and biotechs will participate as well, although gains will have a ceiling.
In this article: ACAD, ARQL, MNTA, SGEN, MDCO, ARWR, KPTI, RDUS, FLXN, RETA, ZYME, DRNA, TCDA, DCPH, APLS, ACHN, ALXN, VRTX, ALDR, RARX, DOVA
Read
Teva, Momenta Slide After Mylan Gets Earlier Than Expected MS Drug Nod
Article By: The Fly
Wednesday, October 4, 2017 2:52 PM EDT
Shares of Mylan are soaring after the company announced that the Food and Drug Administration had approved its generic version of Teva Pharmaceutical's multiple sclerosis treatment Copaxone.
In this article: MYL Also: PFE, MNTA, TEVA
Read
Teva Hires Kare Schultz As CEO: Is A Recovery In The Cards?
Article By: Zacks Investment Research
Monday, September 11, 2017 10:04 AM EDT
Teva Pharmaceutical Industries Limited announced the appointment of Kåre Schultz as president and chief executive officer, thus ending the Israeli generic maker’s long search for a permanent CEO. Share rose more than 12% in pre-market trading.
In this article: TEVA Also: NVO, MNTA, MYL
Read
Small Cap Best And Worst Stocks - Thursday, May 18
Article By: E.B. Capital Markets
Thursday, May 18, 2017 7:37 AM EDT
The average small cap score is 48.99 and the average score over the past four weeks is 49.99.
In this article: ELLI, EVC, MNTA, ASTE, CNMD, ICUI, KTOS, MMSI, WRLD, DCTH
Read
BofA Says Buy Teva With Copaxone Patent Loss Out Of The Way
Article By: The Fly
Tuesday, January 31, 2017 1:20 PM EDT
Shares of Teva Pharmaceutical are sliding after a judge invalidated four patents for its Copaxone drug, an immunosuppressant for the treatment of relapsing-remitting multiple sclerosis.
In this article: TEVA Also: MNTA, NVS
Read
All Posts

Latest Tweets for $MNTA

No tweets yet!

PARTNER HEADLINES